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relative effectiveness of different 
medical interventions is needed to 
improve the quality and value of 
care, some view CER with skepti-
cism. Recently, the Partnership to 
Improve Patient Care, a coalition 
of 36 industry, patient-advocacy, 
and clinician organizations, raised 
concerns that CER will not take 
adequate account of individual pa-
tient differences and may impede 
the development and adoption of 
improvements in medical care and 
“stymie progress in personalized 
medicine.”1
The controversy stems in part 
from a perceived contradiction be-
tween the concepts of CER and 
personalized medicine. In CER, 
groups of patients are analyzed to 
compare the effectiveness of al-
ternative medical strategies, with 
the intent of informing clinical 
decisions and policies affecting 
health care. The very name “per-
sonalized medicine” suggests an 
approach to care that is based on 
individuals rather than groups. 
The term has been used to de-
scribe the consideration of char-
acteristics such as age, coexist-
ing conditions, preferences, and 
beliefs in crafting an individual 
management strategy; the use of 
advanced individual genomic in-
formation  in  choosing  an  ex-
pensive biologic agent; and the 
development of therapies biolog-
ically tailored to patient needs, 
such as customized monoclonal 
antibodies and vaccines. But far 
from impeding personalized med-
icine, CER offers a way to has-
ten  the  discovery  of  the  best   
approaches  to  personalization, 
providing more and better infor-
mation  with  which  to  craft  a 
management strategy for each in-
dividual patient.
Perhaps the most prominent 
examples of modern personalized 
medicine are genomic tests de-
signed to guide treatment choices 
(see table). Some are widely rec-
ognized as useful, such as testing 
for human epidermal growth fac-
tor receptor type 2 (HER2,  also 
referred to as HER2/neu) to select 
patients with breast cancer who 
will  benefit  from  trastuzumab 
and of testing for the KRAS mu-
tation to determine who is likely 
to benefit from therapies inhibit-
ing the epidermal growth factor 
receptor. Genomic medicine, how-
ever, has had little impact to date 
in most areas of care — a fact 
that some critics blame on pay-
ers,  claiming  that  they  impose 
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T
he American Reinvestment and Recovery Act 
gives comparative-effectiveness research (CER) 
a large boost in funding over the next 2 years. De-
spite a consensus that better information about the 
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unrealistically high evidence bar-
riers  before  agreeing  to  pay  for 
genomic  tests.  But  payers  have 
often  championed  personalized 
approaches  —  for  example,  by 
reimbursing  for  KRAS  testing 
before  the  Food  and  Drug  Ad-
ministration (FDA) has fully em-
braced it. The real bottleneck is 
often the science itself: progress 
in identifying clinically important 
genetic variants has been slow, 
since seldom does the presence 
of a common variant greatly in-
crease the relative risk of a seri-
ous  disease  or  of  severe  harm 
from treatment. Moreover, only 
some genomic tests provide clin-
ically important information. For 
example, although the FDA en-
dorsed the use of genomic tests 
to identify persons with warfa-
rin sensitivity, comparative trials 
showed that the tests added little 
value over careful monitoring of 
the international normalized ra-
tio.2 Chromosomal mutation 9p21.3 
is associated with increased risk of 
cardiovascular disease in women, 
but a recent study showed that 
knowledge of its presence adds no 
additional predictive pow  er to the 
standard information on risk.3
The  greatest  obstacle  to  the 
adoption of personalized approach-
es such as genomic testing, how-
ever,  is  the  lack  of  adequately 
designed studies assessing their 
clinical utility. Often there is lit-
tle consensus about the best way 
to  design  and  implement  such 
studies. We may know very little 
about how a test might improve 
health in typical clinical settings. 
These are precisely the kinds of 
issues that CER is designed to ad-
dress. As the leaders of the Na-
tional  Heart,  Lung,  and  Blood 
Institute recently argued, once as-
sociations between genotype and 
drug sensitivity have been identi-
fied, studies assessing the clinical 
benefits of gene-guided manage-
ment strategies will be needed.4 
Without knowing how well these 
strategies work, physicians can’t 
easily apply them or convince pa-
tients  that  a  test  is  worth  the 
out-of-pocket cost. In the case of 
tests  that  determine  whether  a 
patient is likely to benefit from 
a cancer-preventive, such as tamox-
ifen,  a  misleading  result  could 
lead either to unnecessary expo-
sure to side effects or a failure to 
reduce an elevated risk of can-
cer. Appropriately designed stud-
ies could reveal that a genomic 
test adds little useful information 
or, conversely, that the personal-
ized approach works better.
Physicians, recognizing that pa-
tients’ responses to treatment vary, 
have long tried to make treatment 
decisions that are as relevant to 
the individual patient as possible. 
In doing so, they have had to bal-
ance the findings of formal stud-
ies with clinical judgment: with-
out the guidance of well-designed 
studies, physicians’ hunches about 
the effectiveness of treatments are 
frequently wrong, but the right 
kinds of studies have not always 
been available. There may be no 
high-quality  studies  of  a  treat-
ment, or the patient or the treat-
ment being considered may differ 
in  important  ways  from  those 
already studied.
For many years, clinical epide-
miology  and  related  fields  have 
sought to improve our understand-
ing of treatment effects at the indi-
vidual level by analyzing subgroup 
effects and developing clinical pre-
diction rules. Yet with too few ap-
propriately designed studies, phy-
sicians, patients, and families have 
often  had  little  guidance  about 
which patients were most likely to 
benefit from a clinical strategy. 
Perhaps the most important goal 
of CER is to broaden and deepen 
such information, providing tools 
for matching medical care much 
more precisely to individual pa-
tients.
Although CER’s methods are 
not entirely new, the federal ini-
tiative will support research that 
is both more comprehensive — 
encompassing many more treat-
ments and conditions, as well as 
more complete outcome measures 
— and more relevant to real-world 
clinical decisions than tradition-
al clinical research. For example, 
large observational databases and 
pooled trial results can be used to 
learn more about the subgroups 
of patients who benefit from ther-
apy. A recent study showed that 
mortality was similar overall for 
patients  with  coronary  disease 
whether treated with percutaneous 
coronary intervention (PCI) or cor-
onary-artery bypass surgery. How-
ever, the results varied strikingly 
with age: mortality was much low-
er with surgery among patients 
65 years of age or older and lower 
with PCI among those 55 years 
of age or younger.5 Such informa-
tion is important not only for pa-
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Selected Genomic Biomarkers.
Biomarker Disease Drug
c-kit Gastrointestinal stromal 
tumor
Imatinib mesylate
CCR5 Human immunodefi-
ciency virus
Maraviroc
Cytochrome P-450  
variants
Various disorders Warfarin, voriconazole
EGFR Non–small-cell lung  
cancer
Erlotinib
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tients with varying risk character-
istics and coexisting conditions 
but for women, members of mi-
nority  groups,  and  others  who 
have historically been underrep-
resented in clinical trials. Current 
CER efforts aim to ensure that 
much more useful data will be 
collected and that better methods 
will be developed for understand-
ing  differences  in  effectiveness 
among different patient groups.
As CER guides individual pa-
tient care, it will also guide and 
promote innovation. In some cas-
es, federal support of the research 
will reduce the development costs 
of  new  medical  technologies. 
Emerging CER methods promise 
to be more rapid, relevant, and 
efficient. Furthermore, the devel-
opment of explicit standards for 
CER  methodology  will  help  to 
clarify which forms of evidence 
are  sufficiently  informative  for 
health care decision makers — 
an advance that will be particu-
larly important for the most nov-
el personalized approaches, such 
as  the  creation  of  monoclonal 
antibodies directed against a can-
cer  in  a  specific  patient.  Such 
exciting prospects do not obvi-
ate the need for evaluation; they 
change  the  kind  of  evaluation 
that is needed. CER may well re-
quire  innovative  approaches  to 
clinical trials — such as adap-
tive,  pragmatic,  or  other  novel 
trial designs. Individualized ther-
apies might be evaluated through 
the random assignment of patients 
to tailored therapy or a conven-
tional  alternative;  such  an  ap-
proach would neither disadvan-
tage the personalized therapy nor 
presume its superiority.
The deepest concern about CER 
is that it will be misused, which is 
why some legislators seek to pro-
hibit information on comparative 
effectiveness from influencing cov-
erage policy and payment deci-
sions. But surely these decisions 
will not be improved by discour-
aging the use of the most relevant 
and valid information about what 
works and in whom. CER is not a 
panacea, but it is a key to individ-
ualized care and innovation, not a 
threat. An initiative to advance our 
knowledge about the effectiveness 
of clinical strategies can hasten 
the day when personalized medi-
cine transforms health care.
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T
he proposal to include $1.1 
billion for comparative-effec-
tiveness research (CER) in the fed-
eral stimulus package encountered 
a vigorous and well-coordinated 
backlash. The campaign to gut 
this funding ultimately failed, but 
the debate it engendered and the 
resonance of the opposition’s ar-
guments in both lay and policy 
circles reveal much about the is-
sues that will surround such re-
search and its application in the 
coming years.
The contested provisions were 
designed to support studies com-
paring the efficacy and safety (and, 
by extension, the cost-effective-
ness) of alternative ways of ad-
dressing common clinical prob-
lems. Interventions to be evaluated 
will include pharmaceuticals, de-
vices, procedures, and diagnostic 
approaches, such as imaging stud-
ies.  This  research  will  fill  im-
portant information gaps facing 
clinicians,  patients,  and  payers 
concerning what works best. Cur-
rently, the Food and Drug Admin-
istration (FDA) often approves new 
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